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Objectives. We sought to evaluate the immediate angiographic
results and intermediate-term follow-up after percutaneous treat-
ment of left main coronary stenoses in the new device era.
Background. Historically, balloon angioplasty of left main
coronary stenoses has been associated with high procedural
morbidity and poor long-term results. It is not clear whether new
devices are more effective in this anatomic setting.
Methods. Between July 1993 and July 1995, we performed
initial left main coronary interventions on 46 patients (mean age
67 6 12 years, 26% women). Quantitative angiography was
available for 42 of 46 interventions, and clinical follow-up was
obtained for all patients at 1 month, 6 months and 1 year after
initial revascularization.
Results. Most interventions (42 of 46) were performed in
patients with “protected” coronary stenoses to the left coronary
system owing to the presence of one or more patent left main
coronary grafts. Seventy-seven percent of screened patients were
deemed unsuitable for repeat coronary artery bypass surgery.
Procedures performed included stenting in 73% of patients (alone
in 30% and after rotational atherectomy in 43%), rotational
atherectomy in 58% (alone in 15% and before stenting in 43%),
directional atherectomy in 4% and angioplasty alone in 7%. Initial
procedural success was achieved in all interventions, with no
deaths, myocardial infarctions (creatine kinase, MB fraction >50
IU/liter) or emergent bypass surgery. Follow-up data to date
(median duration 9 months, range 6 to 19) demonstrate a 98%
overall survival rate and a 6-month event-free survival rate of 78%
(six target vessel revascularizations [TVRs], four non-TVRs).
Conclusions. Treatment of protected left main coronary artery
stenoses can be accomplished safely and effectively with new
device technology. Intermediate-term follow-up demonstrates an
acceptably low rate of death, myocardial infarction or repeat
revascularization at 6 months and 1 year.
(J Am Coll Cardiol 1997;29:345–52)
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Left main coronary artery disease has a poor prognosis with
medical treatment (1,2). Based on randomized trials and large
registries demonstrating that coronary artery bypass graft
surgery leads to striking survival benefits and improved symp-
tomatic status in patients with significant left main coronary
artery stenoses, surgical revascularization has become standard
therapy for patients with this condition (3–6). In contrast,
percutaneous transluminal coronary angioplasty (PTCA) has
generally been avoided in such patients because of problems
such as hemodynamic compromise during balloon inflation,
the disastrous consequences of abrupt vessel closure and high
rates of restenosis (7). In addition, these lesions tend to be
heavily calcified and highly elastic, and thus are often techni-
cally challenging to treat with conventional balloon angio-
plasty. Nevertheless, several investigators have attempted
PTCA for selected left main coronary lesions with good
immediate angiographic and procedural results (8–13), partic-
ularly in patients with “protected” left main coronary artery
stenoses—that is, patients with at least one patent coronary
artery bypass graft supplying the left coronary artery system. In
general, these series demonstrate typical PTCA results—
residual stenoses of 20% to 30%, with restenosis necessitating
repeat revascularization in 30% to 40% of patients over the
next 6 to 12 months (8–13).
Recently, the availability of new devices has rekindled
interest in percutaneous treatment of left main coronary artery
stenoses. The potential advantages of these devices for left
main coronary artery interventions include increased predict-
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ability of the immediate result as well as a lower risk of
dissection and abrupt closure, which may be life-threatening in
this condition. In addition, debulking procedures, such as
directional coronary atherectomy (DCA) and percutaneous
transcoronary rotational atherectomy (PTCRA) may limit
elastic recoil. Stents could also limit elastic recoil and further
improve post-treatment minimal lumen diameter (MLD),
thereby reducing the incidence of subsequent restenosis in this
high risk subset of patients. To date, publications of the results
of new device treatment for left main coronary artery stenoses
have consisted only of small series and case reports have had
limited follow-up (14–19). Accordingly, this report describes
the immediate procedural outcomes, immediate angiographic
results and 1-year follow-up of our experience with percutane-
ous revascularization of left main coronary stenoses in the new
device era.
Methods
Patient group. Between July 1993 and July 1995, we per-
formed 54 left main coronary artery interventions on 50
patients at Beth Israel Hospital in Boston, representing 2.5%
of all interventions during this time. Four such procedures
(7%) were performed emergently for acute myocardial infarc-
tion, cardiogenic shock or cardiac arrest and were excluded
from this study. In addition, four patients underwent a repeat
left main coronary intervention for restenosis after PTCA (one
patient) or stent placement (two patients) or for subacute
thrombosis subsequently treated with stent placement (one
patient). These repeat procedures were also excluded from the
analysis. Thus, the study group consisted of 46 patients who
underwent an initial left main coronary artery intervention. All
patients undergoing an elective left main coronary artery
intervention had objective evidence of myocardial ischemia
and$70% visually estimated stenosis of the left main coronary
artery.
Left main coronary artery procedure. The strategy for
treating left main coronary artery stenoses evolved consider-
ably over the study period. Initially, most patients were treated
by either Palmaz-Schatz coronary stent implantation (Johnson
& Johnson Interventional Systems) (Fig. 1) or balloon angio-
plasty alone (if the lesion was deemed to be unsuitable for
stenting). When high speed rotational atherectomy (Rotabla-
tor, Heart Technology) became available at our institution
beginning in October 1993, patients with fluoroscopically visi-
ble calcification of the left main coronary artery were treated
primarily with this procedure. During the last year of the study
period, we used a strategy of pretreating most calcified left
main coronary stenoses with rotational atherectomy followed
by planned coronary stenting whenever feasible (Fig. 2).
Stenting was avoided, however, when the reference vessel
diameter was ,3.0 mm or when the distal runoff was poor.
Directional atherectomy was performed according to stan-
dard techniques (20). Rotational atherectomy was performed
using a “stepped burr” approach as previously described (21),
generally beginning with a 1.5- or 1.75-mm burr and increasing
to a final burr size corresponding to 60% to 80% of the
reference vessel diameter. During rotational ablation, the
operator attempted to minimize forward pressure to minimize
heat generation and maintain a burr speed within 5,000 rpm of
the initial “platform.” Left main coronary artery stenting
was performed only after pretreatment with either PTCA or
PTCRA using Palmaz-Schatz intracoronary stents, Gianturco-
Roubin stents (Cook Inc.) or Palmaz-Schatz biliary stents
(Johnson & Johnson Interventional Systems) as previously
Abbreviations and Acronyms
DCA 5 directional coronary atherectomy
IMA 5 internal mammary artery
LAD 5 left anterior descending coronary artery
LCx 5 left circumflex coronary artery
MLD 5 mimimal lumen diameter
PTCA 5 percutaneous transluminal coronary angioplasty
PTCRA5 percutaneous transcoronary rotational atherectomy
TVR 5 target vessel revascularization
Figure 1. Left coronary angiogram demonstrating
left main coronary artery stent procedure in a 66-
year old man who underwent coronary artery bypass
graft surgery 4 months earlier, but presented with
recurrent angina, a patent internal mammary graft
and an occluded vein graft to the left circumflex
coronary artery system. Top left, Baseline anteropos-
terior view reveals a 78% ostial and mid left main
stenosis (arrow) supplying a large left circumflex
coronary artery. After placement of a 0.014-in. extra
support guide wire in the left circumflex coronary
artery and predilating with a 2.5-mm balloon, a
4.0-mm 3 10-mm biliary stent was deployed across
the left main coronary lesion (bottom left, bidirec-
tional arrow). High pressure dilation was performed
with a 4.0-mm noncompliant balloon to fully expand
the stent (bottom right, open arrow), resulting in a
residual stenosis of 215% (top right, arrow).
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described (22,23). All stenting procedures were concluded with
high pressure postdilation at .12 atm, and all balloon infla-
tions were limited to #30 s. Prophylactic intra-aortic balloon
counterpulsation was used in all patients with unprotected left
main coronary stenoses (n 5 4) and in other patients with
poorly protected left coronary system anatomy, severe left
ventricular dysfunction or markedly elevated filling pressures,
at the discretion of the operator (n 5 9). Intravascular
ultrasound imaging was performed during only two interven-
tions (4%).
During left main coronary intervention, all patients re-
ceived intravenous heparin to maintain an activated clotting
time .300 s. No patients received abciximab, dextran or
intracoronary thrombolytic therapy. After successful revascu-
larization, all patients who received a stent were treated with
aspirin, either dipyridamole (through May 1994) or ticlopidine
(after May 1994) and warfarin. Vascular access sheaths were
removed 4 to 6 h later when the activated clotting time was
,180 s. Once adequate hemostasis was obtained, intravenous
heparin was restarted and continued until therapeutic oral
anticoagulation (international normalized ratio 2.0 to 3.5) was
achieved in all patients. After hospital discharge, warfarin and
either dipyridamole or ticlopidine were continued for 4 weeks,
and aspirin was continued indefinitely. Further management
was guided by the patients’ primary physician.
Angiographic analysis. Quantitative angiographic analysis
was performed using hand-held digital electronic calipers
(Max-Cal, Fowler & NSK), using the 9 or 10F guiding catheter
as a reference as previously described (20). This method has
been previously shown (24) to be reliably reproducible and to
correlate closely with computerized digital image analysis.
Preinterventional and postinterventional analyses were per-
formed in the identical working view, generally a shallow right
anterior oblique caudal view to maximize visualization of the
length and severity of the left main coronary stenosis (25–27).
The reference vessel was considered to be the diameter of the
angiographically normal caliber left main coronary artery
proximal (if present) or distal to the lesion. If no angiographi-
cally normal segment of the left main coronary artery was
present, however, the reference segment was estimated as the
largest diameter of the uninvolved proximal left anterior
descending coronary artery (LAD) or left circumflex coronary
artery (LCx) artery.
Angiographic success was defined as achievement of a
residual diameter stenosis #50%. Procedural success was
defined as angiographic success in the absence of any major
complication (in-laboratory death, Q wave myocardial infarc-
tion or emergency coronary artery bypass graft surgery).
Follow-up. Clinical follow-up was obtained for all patients
at 1 month, 6 months and 1 year after initial revascularization,
and annually thereafter to determine each patient’s symptom-
atic status and need for subsequent revascularization.
Follow-up was performed by telephone contact with the pa-
tient or his or her primary physician, or both. When necessary,
this information was supplemented by a review of hospital
discharge summaries, the medical record and coronary angio-
graphic data. Routine angiographic follow-up was not per-
formed during the study period. Target vessel revascularization
(TVR) was defined as any coronary artery bypass graft to the
left main coronary system or any repeat percutaneous revas-
cularization to the left main coronary artery during follow-up.
In contrast, non-TVR was considered to be any subsequent
percutaneous revascularization that was performed outside the
anatomic boundary of the left main coronary artery.
Statistical analysis. Discrete data are presented as fre-
quencies, and continuous data are presented as mean 6 SD.
Continuous data were compared using the Student t test
(paired or unpaired, as appropriate), and frequencies were
compared using the Fisher exact test. A p value ,0.05 was
considered statistically significant. Estimates of overall and
event-free survival were determined from the time of each
patient’s first left main coronary intervention using the Kaplan-
Meier method (28).
Figure 2. Left coronary angiogram demonstrating a combined rota-
tional atherectomy and stent procedure in the left main coronary
artery of a 47-year old man who underwent coronary artery bypass
graft surgery 7 years earlier, but presented with progressive angina and
only one patent graft to the left coronary artery system. Top, Baseline
right anterior oblique view shows an 84% mid left main stenosis
(arrow). After placement of a 0.017-in. type C guide wire in the left
anterior descending coronary artery, rotational atherectomy was per-
formed with a 1.75-mm burr (second panel from top) for 30 to 45 s,
resulting in a residual stenosis of 40% (third panel from top). Bottom,
After deployment of a 3.5-mm Palmaz-Schatz coronary stent (bidirec-
tional arrow) and high pressure dilation using a 4.0-mm noncompliant
balloon, there was 12% residual stenosis.
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Results
Patient characteristics. The characteristics of the 46 pa-
tients are described in Table 1. The patients’ mean age was
67 6 12 years, and most patients were men (74%). Ninety-
three percent (43 of 46) of the patients had undergone bypass
surgery a mean of 5.5 years (range 0.2 to 17.7) before the left
main intervention. Six patients (12%) had undergone two or
more coronary artery bypass operations. In general, patients
were selected for percutaneous intervention after being re-
fused elective or emergent operation (22%), or because of a
decision to avoid repeat bypass surgery due to either a patent
internal mammary artery (IMA) or the presence of two or
more patent grafts to the left coronary artery system. Most
patients had Canadian Cardiovascular Society class III (22%)
or IV (54%) angina at the time of the left main coronary
intervention.
Forty-two (91%) of 46 interventions were performed on
patients with protected left main coronary stenoses owing to
the presence of one or more patent grafts to the left main
coronary system. Sixty-one percent (28 of 46) of interventions
were performed in the setting of a single patent graft to either
the LAD or LCx system, whereas 30% (14 of 46) of interven-
tions were performed with patent grafts to both the LAD and
LCx systems. A patent IMA graft was present in 65% of
patients. In those patients with multiple patent grafts, left main
coronary intervention was generally performed to revascular-
ize a large intermedius or diagonal branch that was not
supplied by a patent graft and that was thought to represent a
culprit vessel on either anatomic or electrocardiographic
grounds.
The remaining four interventions were performed on un-
protected left main coronary stenoses in patients who had been
turned down for elective bypass surgery. One of these patients
had previously undergone single-vessel bypass surgery to the
right coronary artery, and the graft was patent at the time of
left main coronary intervention. The native right coronary
artery was patent in the other three patients who underwent
unprotected left main coronary interventions. There were no
angiographically visible collateral channels from the right
coronary artery to the left main coronary system in any of these
patients.
In-hospital results and complications. Left main coronary
artery revascularization was performed using a single tech-
nique in 26 procedures (56%); these included balloon angio-
plasty alone in 3 (7%), directional atherectomy in 2 (4%),
rotational atherectomy in 7 (15%) and stenting in 14 (30%)
(Fig. 3). In addition, rotational atherectomy followed by stent-
ing was used in 20 patients (43%). Stenting was generally
performed with the Palmaz-Schatz coronary stent (79%), but
eight patients (24%) received Palmaz-Schatz biliary stents, and
one patient (2%) received a Gianturco-Roubin stent. Prophy-
lactic intra-aortic balloon pumps were placed in 13 patients
(28%). All attempts at left main coronary intervention were
successful in reducing the postprocedural residual stenosis to
,50% (angiographic success 100%). Moreover, no patients
died, required emergency bypass surgery or suffered a Q wave
myocardial infarction before hospital discharge. Minor com-
plications occurred in 26% of interventions and consisted
primarily of the need for blood transfusion after the pro-
cedure (20%). Other minor complications, including surgical
vascular repair (6%) and mild (.20 IU/liter, 6%) or moderate
(.50 IU/liter, 0%) postprocedure creatine kinase-MB fraction
elevation, were infrequent.
Immediate angiographic results. Angiographic data were
available for 42 of 46 interventions (Table 2). Quantitative
angiography could not be performed for the remaining four
interventions because of incomplete angiographic information
or missing cineangiograms. Aorto-ostial left main coronary
Figure 3. Distribution of left main coronary artery interventions by
procedure type. DCA 5 directional coronary atherectomy; PTCA 5
percutaneous transluminal coronary angioplasty; PTCRA 5 percuta-
neous transcoronary rotational atherectomy. (Percentages do not total
100% owing to rounding errors.)
Table 1. Baseline Characteristics of 46 Patients Who Underwent
Elective Left Main Coronary Artery Interventions
Age (yr) 67 6 12
Male (%) 34 (74)
Hypertension (%) 26 (56)
Hypercholesterolemia (%) 31 (67)
Cigarette smoking (%) 14 (30)
Diabetes mellitus (%) 12 (26)
Family history of CAD (%) 17 (37)
CCS class (%)
0 3 (7)
I 0 (0)
II 8 (17)
III 10 (22)
IV 25 (54)
Previous bypass surgery (%) 43 (94)
Patent IMA graft (%) 30 (65)
Recent MI (%) 9 (20)
LVEF (%) 50 6 14
Data presented are mean value 6 SD or number (%) of patients. CAD 5
coronary artery disease; CCS 5 Canadian Cardiovascular Society; IMA 5
internal mammary artery; LVEF 5 left ventricular ejection fraction;
MI 5 myocardial infarction.
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stenoses, defined as $50% stenosis occurring within 5 mm of
the left main coronary artery origin from the aorta, were
present in 41% of cases. Moderate or heavy fluoroscopic
calcium was present in 74% of cases. In the overall group, the
mean preprocedure MLD was 0.98 6 0.48 mm, with an
associated mean percent diameter stenosis of 74 6 11%. After
the left main coronary intervention, the reference diameter
was unchanged, but the final MLD increased to 3.27 6
0.91 mm, resulting in a mean percent diameter stenosis of 106
24%.
Impact of stenting on immediate angiographic results. Pre-
vious studies have demonstrated that stent implantation re-
duces elastic recoil, thus improving immediate and long-term
angiographic results, compared with conventional PTCA (29).
In our series, patients treated with or without coronary stent
implantation had similar reference vessel diameters (3.63 6
0.80 vs. 3.916 1.04 mm, p5 0.36; Table 3) and similar degrees
of calcification (71% vs. 82%, p 5 0.48). As expected, stenting
of left main coronary stenoses compared with nonstent treat-
ments resulted in larger acute gains (2.52 vs. 1.63 mm, p 5
0.004), larger final postprocedure minimal lumen diameters
(3.53 6 0.74 vs. 2.51 6 0.97 mm, p , 0.001) and lower residual
stenoses (3 6 21% vs. 30 6 24%, p 5 0.001).
Subgroup analysis demonstrated that the benefits of left
main coronary stenting were most pronounced for aorto-ostial
lesions (Table 4). For aorto-ostial lesions, patients treated with
stent implantation achieved a larger final MLD (3.596 0.92 vs.
2.21 6 0.81 mm, p 5 0.006) and a smaller residual stenosis
(27 6 25 vs. 33 6 27%, p 5 0.008) compared with patients
treated without a stent. In contrast, for nonostial left main
coronary stenoses, the benefits of stent implantation were less
apparent in terms of either MLD (stented 3.50 6 0.66 vs.
nonstented 3.06 6 1.11 mm, p 5 0.27) or residual stenosis
(stented 9 6 17% vs. nonstented 25 6 20%, p 5 0.10).
However, given the small number of patients in this subgroup,
the power of our study to detect a 16% difference in percent
residual stenosis was only 41%.
Impact of rotational ablation. As noted, mid-way through
this series we instituted a strategy of performing rotational
atherectomy before stent placement to treat highly complex,
calcified left main coronary lesions. In the overall series,
treatment with rotational ablation plus stenting was not asso-
ciated with a significant improvement in immediate angio-
graphic outcomes (final MLD: 3.43 6 0.63 mm; percent
diameter stenosis: 2 6 22%) compared with stenting alone
(final MLD: 3.67 6 0.87 mm, p 5 0.39; percent diameter
stenosis: 5 6 20%; p 5 0.65). Among those lesions with
fluoroscopic calcification, however, the use of rotational
atherectomy before stent placement did yield somewhat lower
residual stenoses (0 6 20% vs. 14 6 18%, p 5 0.07).
Clinical follow-up. Clinical follow-up was available for
100% of treated patients with a minimal follow-up duration of
6 months (median follow-up 9 months, range 6 to 19). At the
last follow-up, one patient had died and one patient had
Table 2. Baseline Angiographic Characteristics and Immediate
Procedural Results for 42 Interventions*
Lesion characteristics
Aorto-ostial 17 (41%)
Calcified 31 (74%)
Measurements
Preprocedure
Lesion length (mm) 3.73 6 2.16
Ref vessel diameter (mm) 3.706 0.87
MLD (mm) 0.98 6 0.48
% stenosis 74 6 11
Postprocedure
Ref vessel diameter (mm) 3.726 0.90
MLD (mm) 3.27 6 0.91†
% stenosis 10 6 24†
*Quantitative coronary angiography could not be performed in 4 of 46
interventions because of incomplete angiographic views or missing cineangio-
grams. †p , 0.001 versus preprocedure measurement. Data presented are mean
value6 SD or number (%) of patients. MLD5minimal lumen diameter; Ref5
reference.
Table 3. Immediate Angiographic Results: Nonstented Versus
Stented Lesions
Measurement
Nonstented
(n 5 11)
Stented
(n 5 31) p Value
Preprocedure
Ref vessel diameter (mm) 3.91 6 1.04 3.63 6 0.80 0.36
MLD (mm) 0.88 6 0.31 1.01 6 0.52 0.45
% stenosis 77 6 8 72 6 11 0.28
Postprocedure
Ref vessel diameter (mm) 3.58 6 0.82 3.77 6 0.93 0.55
MLD (mm) 2.51 6 0.97 3.53 6 0.74 ,0.001
% stenosis 30 6 24 3 6 21 0.001
Data are presented as mean value 6 SD. Abbreviations as in Table 2.
Table 4. Immediate Angiographic Results: Nonstented Versus
Stented Left Main Coronary Stenoses Classified by Ostial Location
Measurement Nonstented Stented p Value
Ostial location n 5 7 n 5 10
Preprocedure
Ref vessel diameter (mm) 3.35 6 0.81 3.20 6 0.82 0.70
MLD (mm) 0.92 6 0.31 0.82 6 0.43 0.64
% stenosis 73 6 6 74 6 10 0.67
Postprocedure
Ref vessel diameter (mm) 3.32 6 0.79 3.49 6 1.08 0.73
MLD (mm) 2.21 6 0.81 3.59 6 0.92 0.006
% stenosis 33 6 27 27 6 25 0.008
Nonostial location n 5 4 n 5 21
Preprocedure
Ref vessel diameter (mm) 4.88 6 0.60 3.83 6 0.72 0.01
MLD (mm) 0.83 6 0.34 1.10 6 0.55 0.35
% stenosis 83 6 6 71 6 12 0.08
Postprocedure
Ref vessel diameter (mm) 4.02 6 0.76 3.90 6 0.85 0.79
MLD (mm) 3.06 6 1.11 3.50 6 0.66 0.27
% stenosis 25 6 20 9 6 17 0.10
Data presented are mean value 6 SD. Abbreviations as in Table 2.
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suffered a Q wave myocardial infarction (3.5 months after
treatment) and subsequently underwent repeat revasculariza-
tion with PTCA. Overall, TVR was performed in six patients
(13%), including one repeat bypass operation and five repeat
percutaneous left main coronary interventions. Repeat revas-
cularization of a non–target vessel was required in another
four patients (9%).
Figure 4 illustrates overall and event-free survival for the
entire cohort. The overall survival rate was 98% at both 6
months and 1 year after the procedure, whereas the event-free
survival rate (freedom from death, myocardial infarction or
any revascularization) was 78% and 71% at 6 months and 1
year, respectively. Although the overall rate of repeat revascu-
larization was 22% at 6 months, the rate of TVR was only 13%.
Discussion
This study describes the results of 46 consecutive left main
coronary interventions performed during the “new device” era
(1993–95) and represents the largest such experience reported
to date. In contrast to previous studies of conventional PTCA
(8–13), we found that treatment of these challenging lesions
with a variety of new technologies, including stents and rota-
tional atherectomy, was both safe and effective. Despite the
presence of numerous high risk clinical and angiographic
characteristics (previous bypass surgery, advanced age and
heavy calcification), procedural success in this series was 100%,
with no major in-hospital complications. Moreover, the use of
specific new device technology resulted in excellent immediate
angiographic outcomes. In fact, the mean final diameter
stenosis of 10% in this series approaches the best angiographic
outcomes that have been reported for treatment of other, more
favorable lesion locations with these devices (20–23). Finally,
clinical follow-up demonstrates that the initial benefit of these
procedures was generally maintained. At 1-year follow-up, the
overall event-free survival rate was 71%, with target vessel
failure in only 13% of patients.
Comparison with previous studies. Several previous stud-
ies have described the results of left main coronary artery
revascularization, primarily using conventional balloon angio-
plasty (PTCA) (8–13). In the largest published series, O’Keefe
et al. (8) performed PTCA of the left main coronary artery in
127 lesions, 97 (76%) of which were “protected.” Although
angiographic success was achieved in 94% of elective cases,
procedural mortality was 2.4% in “protected” interventions
and 9.1% in “unprotected” interventions. Other series have
reported similar results (9–13). Moreover, although left main
coronary artery balloon angioplasty is initially successful in
90% to 95% of patients, the unsuccessful attempts have
typically resulted in major complications (death, myocardial
infarction or emergency bypass surgery) (9,12,13), limiting the
utility of this procedure. Finally, balloon angioplasty of left
main coronary artery stenoses has typically resulted in residual
stenoses of 20% to 35%, leading to restenosis and the need for
repeat revascularization in 30% to 50% of patients (9,12,13).
For example, O’Keefe et al. (8) reported that during a mean
follow-up period of 20 months, repeat revascularization was
performed after 37% of “protected” and 42% of “unpro-
tected” interventions, including TVR in 25% and 38%, respec-
tively. Although the results of DCA for left main coronary
artery stenoses have been somewhat more favorable (13%
mean residual stenosis, 89% 6-month event-free survival rate),
its use remains limited by technical difficulty in delivering the
rigid atherectomy housing into these often calcified lesions
(18).
Compared with these published data, our results using a
lesion-specific approach that begins with rotational atherec-
tomy for calcified lesions and generally finishes with adjunctive
coronary stenting with high pressure balloon dilation, are quite
favorable. Using this approach, we achieved procedural suc-
cess in 100% of patients with a low (10%) mean residual
stenosis and no major complications. Given the excellent
immediate angiographic results in these procedures, the rela-
tively low (13%) incidence of subsequent TVR is not surpris-
ing.
Device selection/technical considerations. Despite the rel-
atively small size of our series, certain useful insights may be
derived from our experience. The use of coronary stents, either
alone or after initial rotational atherectomy, produces the best
immediate angiographic results (Table 3). These findings are
consistent with the benefits that have been demonstrated for
stenting in other lesion locations (29,30). Not surprisingly, we
found that the benefits of stenting to treat left main coronary
artery stenoses were most pronounced for aorto-ostial lesions
(Table 4), which are generally troubled by elastic recoil
(14,26,31–35). In our series, stenting for aorto-ostial disease
was associated with much lower mean residual stenoses than
any other nonstent treatment (27% vs. 33%, p 5 0.008). For
nonostial lesions, however, the immediate angiographic bene-
fits of stenting were fewer.
Although the benefits of stenting for aorto-ostial left main
coronary lesions are striking, these procedures are nonetheless
challenging. Proper stent positioning is critical to resist recoil
Figure 4. Kaplan-Meier estimates of overall and event-free survival
among 46 patients who underwent treatment of left main coronary
stenoses. MI 5 myocardial infarction; TVR 5 target vessel revascu-
larization.
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and requires identification of an angiographic view that pre-
cisely defines the limits of the aortic wall. To avoid missing the
true ostium, we have generally favored an approach of allowing
the stent to protrude 1 to 2 mm into the aortic lumen and using
a balloon to “flare” the end of the stent against the aortic wall.
In addition, the use of biliary stents, given their greater radial
strength and radiopacity, offers certain advantages in this
location.
Finally, our data suggest that pretreatment of heavily
calcified left main coronary artery lesions with rotational
atherectomy before stenting may improve stent deliverability
and expansion, with improved short-term results. Specifically,
the use of a combination of rotational ablation and stenting for
calcified lesions was associated with a lower postprocedure
residual stenosis than stenting alone (0% vs. 14%, p 5 0.07).
This appears to be a classic example of “transdevice synergy,”
in which pretreatment with rotational atherectomy debulks
and decalcifies the lesion so as to facilitate optimal stent
deployment (36). Despite their lower postprocedure residual
stenoses, patients treated with rotational atherectomy had a
similar need for later TVR as those patients treated without
rotational atherectomy (15% vs. 11%, p 5 0.61). Nonetheless,
one might speculate that by permitting optimal stent deploy-
ment at lower inflation pressures and allowing the achievement
of lower residual stenoses, this technique might be associated
with less deep tissue injury, less dissection and possibly less
neointimal proliferation and restenosis (37–39). These poten-
tial benefits of transdevice synergy, however, remain unproved,
and controlled trials will be necessary to address this issue
directly.
Clinical implications. Our findings have several important
implications for the treatment of left main coronary artery
disease. In patients with myocardial ischemia due to protected
left main coronary artery stenoses, our results suggest that the
use of new coronary devices in a lesion-specific manner is a
safe and effective form of coronary revascularization, and may
be superior to the results offered by conventional balloon
angioplasty. Given the high risk associated with repeat bypass
operations in such patients (who often have a patent IMA
graft, poor distal targets and depressed left ventricular func-
tion) (40), percutaneous revascularization with new devices
may therefore represent the current treatment of choice.
Nonetheless, widespread adoption of stenting or other new
device use for treatment of unprotected left main coronary
stenoses in patients who are acceptable surgical risks would be
premature at this time. Over the past 25 years, bypass surgery
has demonstrated excellent short-term and long-term clinical
results for this condition, with procedural mortality in the 1%
to 2% range and 3-year survival rates .90% (1,3–6). In
contrast, PTCA of unprotected left main coronary stenoses has
demonstrated a short-term mortality as high as 21%, even
when the procedure is performed with percutaneous cardio-
pulmonary support (10). Although the use of stenting has led
to a reduction in short-term ischemic complications of PTCA,
even optimal stenting currently has restenosis rates of 13% to
20% (41). In the setting of an unprotected left main coronary
lesion, the clinical impact of restenosis is unclear, but might
well present as cardiogenic shock or sudden death in this
subset of patients. Thus it is unlikely that percutaneous revas-
cularization will replace bypass surgery for the treatment of
unprotected left main coronary artery disease, at least until the
problem of restenosis has been virtually eliminated. Nonethe-
less, in patients with severe left main coronary artery disease
who are poor surgical candidates, cautious application of new
device percutaneous revascularization (i.e., stenting) may be
appropriate (19).
Study limitations. This study has several important limita-
tions. Although this is the largest series of patients treated with
new devices for revascularization of left main coronary steno-
ses, the number of patients is still small and represents an early
portion of the “learning curve” for these procedures. As with
any observational study, it is possible that our results are
confounded by unmeasured covariates. Thus our conclusions
regarding the benefits of stenting for ostial lesions and the
benefits of rotational ablation for calcified lesions should be
viewed as preliminary and await confirmation by other, larger
series or ideally in a controlled clinical trial. Nonetheless, these
observations are reasonable from a pathophysiologic viewpoint
and mirror the benefits seen with these devices in other
coronary locations (21,29,30,33,34). The duration of clinical
follow-up (median 9 months) in our study was somewhat
limited, and it is possible that longer follow-up will demon-
strate additional clinical events. Recent data, however, suggest
that the restenosis process after stenting is time-limited and
that little progression occurs beyond 6 months (42–44). Thus,
any subsequent events or revascularization procedures are
likely to be due to progression of disease elsewhere in the
coronary artery tree.
Finally, the number of patients with unprotected left main
coronary lesions in the study cohort is too small (four patients)
to evaluate the merits of this procedure. Based on the excellent
results we observed in anatomically similar protected left mains,
however, selective treatment of patients with unprotected
ostial or mid left main coronary lesions (not including the
LAD/LCx bifurcation) might be considered by experienced
centers in patients viewed as high risk for surgery.
Conclusions. To our knowledge, this study provides the
first comprehensive assessment of the impact of new device
technology on the percutaneous revascularization of patients
with protected and unprotected left main coronary artery
disease. It demonstrates that a lesion-specific approach incor-
porating rotational ablation, coronary stents and adjunctive
balloon dilation produces excellent immediate angiographic
results and low procedural complications in the treatment
of these challenging and complex lesions. Moreover,
intermediate-term follow-up demonstrates good clinical out-
comes, including a 1-year survival rate of 98% and freedom
from death, myocardial infarction or repeat TVR at 6 months
of 87%. More studies are needed, however, to elucidate more
fully the role of these devices in various patient subsets,
including “unprotected” and emergent left main coronary
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interventions, and to better define criteria for optimal device
selection.
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